Fayon M, Ladipo Y, Galodé F, Debelleix S, Reix P
Université de Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, F-33000 Bordeaux, France; CHU de Bordeaux, Centre de référence de la mucoviscidose, Centre d'Investigation Clinique (CIC 1401), F-33076 Bordeaux, France.
CHU de la Mère et de l'Enfant LAGUNE de Cotonou, Bénin.
Arch Pediatr. 2016 Dec;23(12S):12S9-12S14. doi: 10.1016/S0929-693X(17)30057-X.
Recent data has shown that lung inflammation and infection subvene very early in very young infants with Cystic Fibrosis (CF). This leads to impaired lung function and structural damage, even in asymptomatic children. In the CF-pig model constitutional airway narrowing is present at birth, and is associated with defective mucus migration, and impaired bacterial clearance. At the age of 3 months, 25% of screened CF infants show decreased lung function. Air trapping is also present in 68% and bronchiectasis in 28% of patients. At the same age, the presence of neutrophil elastase in the bronchoalveolar lavage is an ominous sign since it triples the risk of bronchiectasis at the age of 3 years. Since only very few drug therapies have been validated in the preschool children, adapted clinical trials are warranted in this age group. Early interventions may have a huge impact on the natural history of CF, on the condition of not interfering with normal lung growth.
最近的数据显示,囊性纤维化(CF)的极幼龄婴儿很早就会出现肺部炎症和感染。这会导致肺功能受损和结构破坏,即使是无症状的儿童也是如此。在CF猪模型中,出生时即存在先天性气道狭窄,这与黏液迁移缺陷和细菌清除受损有关。3个月大时,25%接受筛查的CF婴儿肺功能下降。68%的患者存在气体潴留,28%的患者存在支气管扩张。在同一年龄,支气管肺泡灌洗中存在中性粒细胞弹性蛋白酶是一个不祥之兆,因为这会使3岁时发生支气管扩张的风险增加两倍。由于只有极少数药物疗法在学龄前儿童中得到验证,因此该年龄组有必要开展适应性临床试验。早期干预可能会对CF的自然病程产生巨大影响,且不会干扰正常的肺生长。